

Synthetic antibodies for specific recognition and crystallization of structured RNA

Jing-Dong Ye*, Valentina Tereshko†, John K. Frederiksen†, Akiko Koide†, Frederic A. Fellouse‡, Sachdev S. Sidhu‡, Shohei Koide†§, Anthony A. Kossiakoff†§, and Joseph A. Piccirilli*†§

*Department of Chemistry, Howard Hughes Medical Institute, and †Department of Biochemistry and Molecular Biology, University of Chicago, 929 East 57th Street, Chicago, IL 60637; and ‡Department of Protein Engineering, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080

Edited by Alan M. Lambowitz, University of Texas, Austin, TX, and approved November 12, 2007 (received for review September 24, 2007)

Antibodies that bind protein antigens are indispensable in biochemical research and modern medicine. However, knowledge of RNA-binding antibodies and their application in the ever-growing RNA field is lacking. Here we have developed a robust approach using a synthetic phage-display library to select specific antigen-binding fragments (Fabs) targeting a large functional RNA. We have solved the crystal structure of the first Fab–RNA complex at 1.95 Å. Capability in phasing and crystal contact formation suggests that the Fab provides a potentially valuable crystal chaperone for RNA. The crystal structure reveals that the Fab achieves specific RNA binding on a shallow surface with complementarity-determining region (CDR) sequence diversity, length variability, and main-chain conformational plasticity. The Fab–RNA interface also differs significantly from Fab–protein interfaces in amino acid composition and light-chain participation. These findings yield valuable insights for engineering of Fabs as RNA-binding modules and facilitate further development of Fabs as possible therapeutic drugs and biochemical tools to explore RNA biology.

antigen-binding fragments | x-ray crystallography

Antibodies are integral components of the immune system and represent a rapidly growing sector of the biotechnology industry (1, 2). Clinically, antibodies serve as diagnostic markers for disease antigens and play increasingly important roles as therapeutic agents for a wide range of diseases (3). Antibodies also provide invaluable biomedical research tools, serving to define the components and functions of macromolecular complexes, to establish cellular distributions of proteins, and to facilitate structural analysis as chaperones for crystallization of membrane proteins (4–6). Hybridoma and other technologies have yielded antibodies against a vast array of specific antigens (2). An enormous body of literature documents the molecular details of antibody interactions with a variety of antigens, including proteins (7), polysaccharides (8), and small haptens (9). However, much less information (and, in particular, no structural information) exists for antibody–RNA interactions.

The relative absence of antibodies that bind RNA from the immunologic repository is striking, especially considering that recent genome-wide analyses of the metazoan transcriptome have revealed the presence of vast numbers of noncoding RNAs, including silencing RNAs, riboswitches, catalytic RNAs, and a multitude of other functional RNA molecules (10, 11). A large number of these RNAs adopt complex three-dimensional architectures that frequently act in complex with proteins to mediate their biological function (12, 13). Nevertheless, with the exception of a handful of examples, mostly isolated from the sera of autoimmune patients (14–17), we know little about anti-RNA antibodies and their recognition of nucleic acids. This dearth of information reflects our inability to elicit antibodies against RNA by using traditional approaches. RNA appears to lack immunogenic potency (18), and its susceptibility to nuclease degradation prohibits direct immunization of animals, which precludes the use of hybridoma technology for large structured RNAs. A robust platform for obtaining antibodies against RNA would enable the investigation of RNA biology

by using approaches analogous to those that have proven to be extremely effective for the study and therapeutic manipulation of protein–protein interactions.

Using a phage platform for the display of libraries of synthetic antigen-binding fragments (Fabs), we have established a general approach to obtain Fabs that bind to RNA. As an RNA antigen for proof-of-concept experiments, we chose the Δ C209 P4-P6 domain derived from the *Tetrahymena* group I intron, which folds into a well defined three-dimensional structure (19, 20). We demonstrate that Fabs targeting the Δ C209 P4-P6 domain bind with high affinity and specifically recognize the RNA tertiary structure. Crystallization of the Fab2- Δ C209 P4-P6 complex yielded a structure at 1.95-Å resolution, revealing the molecular interactions within an RNA–antibody interface and demonstrating the feasibility of antigen-binding fragments as chaperones for RNA crystallization.

Results

Selection of Δ C209 P4-P6-Binding Fabs. The design of our synthetic naïve library for RNA-binding Fab selection employs a “reduced genetic code” approach (21, 22), in which the solvent-accessible regions of light-chain CDR-L3 and heavy-chain CDR-H1 and H2 are randomized with a binary degenerate codon that encodes equal proportions of Tyr and Ser. For heavy-chain CDR-H3, the CDR that usually contributes most to specific antigen binding (23), we replaced the seven residues with diversified loops of variable lengths (6–17 residues) in which each position was a mixture of 20% Tyr, 15% Ser, 15% Gly, and 50% Z (referred to herein as the YSG library). Z represents an equimolar mixture of all natural amino acids except for Cys, Tyr, Ser, and Gly. We chose this library type as the starting design for RNA targets because it has yielded high-affinity Fabs for a wide variety of protein targets (21, 22, 24).

Initially, we carried out the selection according to the procedure described by Laird-Offringa and Belasco (25) for the U1A RNA binding protein. However, we observed severe enrichment of streptavidin-binding phages after three rounds of selection, presumably reflecting the large exposed streptavidin surface used in target immobilization (Fig. 14). We devised two strategies to circumvent this background binding problem. First, Fab phage libraries were preincubated with streptavidin beads to remove streptavidin binders. Second, after incubation of these prescreened phages with the immobilized RNA target, we used biotinylated RNase A to elute the RNA-binding phages selectively from the

Author contributions: J.-D.Y., A.K., S.S.S., S.K., A.A.K., and J.A.P. designed research; J.-D.Y., V.T., J.K.F., and F.A.F. performed research; and J.-D.Y., V.T., S.K., A.A.K., and J.A.P. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

Data deposition: The atomic coordinates and structure factors have been deposited in the Protein Data Bank, www.pdb.org (PDB ID code 2R8S).

§To whom correspondence may be addressed. E-mail: jpiccir@uchicago.edu, koss@bsd.uchicago.edu, or skoide@uchicago.edu.

This article contains supporting information online at www.pnas.org/cgi/content/full/0709082105/DC1.

© 2007 by The National Academy of Sciences of the USA




Fig. 1. The RNA antigen: Δ C209 P4-P6 independently folding domain derived from *Tetrahymena* group I intron. (A) Δ C209 P4-P6 primary and secondary structure schematic. Residue numbering (102–261) corresponds to the *Tetrahymena* group I intron. Nucleotides in color within the secondary structure represent residues protected from hydroxyl radicals. Brown corresponds to protections arising from the Δ C209 P4-P6 tertiary structure; blue corresponds to additional protections induced by Fab2 binding. Blue boxes indicate the P5a and P5c arms involved in binding to Fab2. Loop L6b (residues 239–247; gray box) adopts a partially disordered conformation in the Fab2- Δ C209 P4-P6 crystals. Filled and open dots indicate canonical Watson–Crick and noncanonical pairs, respectively, as derived from the crystal structure of the Fab2- Δ C209 P4-P6 complex. Brown lines indicate long-range tertiary interactions. The pink box highlights the 5' and 3' terminal nucleotides, which adopt a conformation that is different from the previous Δ C209 P4-P6 structure [Protein Data Bank (PDB) ID code 1HR2] (20). The X moiety (see boxed area at the bottom) at the 3' terminus represents the added RNA sequence (red), which, when hybridized to complementary 19-nt 5' biotinylated DNA oligonucleotide (green), allows immobilization on streptavidin-coated magnetic beads. (B) Ribbon representation of the crystal structure of Fab2- Δ C209 P4-P6 complex. Green and yellow ribbons indicate Fab2 heavy and light chains, respectively. The blue ribbon indicates the RNA backbone. Protein and RNA termini and RNA domains are labeled. Orange sticks show residues protected from hydroxyl radical footprinting upon Fab2 binding.

beads. Biotinylated RNase A allows for convenient removal with streptavidin beads. Moreover, to increase the specificity of the selected Fabs after the first round of selection, we added 20 equivalents of an *Escherichia coli* tRNA mixture as competitors during target phage binding.

Using the strategies described above, we picked seven unique Δ C209 P4-P6-binding Fabs after three rounds of selection (Fig. 2). The overall complementarity-determining region (CDR) sequences of the seven clones show no obvious consensus. In the positions of CDR-L3, H1, and H2, which were diversified with a binomial combination of Tyr and Ser, we observed a preference for Ser (76% actual compared with 50% designed occupancy) over Tyr.

clone	K_d (nM)	CDR-L3					CDR-H1					CDR-H2					CDR-H3																				
		51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75											
Fab2	51±3	S	Y	S	S	P	I	L	Y	S	S	S	I	Y	I	S	S	S	Y	G	Y	T	Y	R	R	A	A	G	M	S	T	Y	G	F	-	D	
Fab5	28±3	S	Y	S	S	L	V	F	S	S	S	S	I	S	I	S	S	S	S	G	Y	T	Y	R	K	A	A	S	Y	S	Y	Y	G	L	-	D	
Fab1	>2000	S	S	S	S	Y	P	I	I	S	S	S	S	I	Y	I	S	S	S	S	G	S	T	Y	R	R	S	Y	S	K	G	T	Y	G	L	-	D
Fab3	850±500	Y	S	Y	Y	P	F	F	S	S	S	S	S	I	S	I	S	S	S	S	S	T	S	R	K	S	R	S	Y	S	Y	I	Y	A	L	-	D
Fab4	152±10	S	S	S	S	L	F	F	S	S	S	S	S	I	S	I	S	S	S	S	G	Y	T	Y	R	R	H	K	S	Y	S	Y	A	F	-	D	
Fab6	207±20	H	Y	T	T	P	P	F	Y	S	S	S	S	M	S	I	S	S	S	Y	G	Y	T	Y	R	S	Y	R	G	K	Y	Y	G	G	-	D	
Fab7	145±9	S	Y	Y	S	L	L	F	S	S	S	S	S	I	S	I	S	S	S	S	S	T	S	R	Y	F	Y	Y	K	K	P	G	L	-	-	D	

Fig. 2. The dissociation constants (K_d) and CDR sequences of antigen-binding fragments selected against immobilized Δ C209 P4-P6. Numbering is according to the Kabat definition (37). Color scheme is as follows: gray, residues not randomized; yellow, Tyr; red, Ser; green, Gly; blue, positively charged residues Arg and Lys. K_d was determined by nitrocellulose filter binding. CDR-L3 of Fab6 has the same sequence as the parental Fab template, which is a result of the stop template not being used for CDR-L3 during construction of the library (47).

Possibly, the importance of Tyr observed in the context of protein targets (22, 24, 26, 27) is diminished in selections against RNA targets. In CDR-H3, positively charged residues are slightly enriched. However, for each of the seven unique Δ C209 P4-P6-binding Fabs, there are no more than two positively charged residues present in CDR-H3, suggesting that these sequences do not simply act like the polyarginine/lysine peptides that often bind nucleic acids nonspecifically.

Affinity and Specificity of the Δ C209 P4-P6-Binding Fabs. The selected Fabs were expressed as soluble proteins and purified (28). Two Fabs, Fab2 and Fab5, bind Δ C209 P4-P6 (without the 3' tail sequence used for immobilization, Fig. 1A) with a K_d of 51 and 28 nM, respectively, as determined by nitrocellulose filter binding (10 mM MgCl₂ and 150 mM NaCl; Fig. 2). Binding constants obtained by using independent methods [competitive phage ELISA (28), surface plasmon resonance, and hydroxyl radical footprinting] were within 2-fold of each other [supporting information (SI) Table 1]. Gel filtration experiments on complexes formed by Fab2 and Δ C209 P4-P6 in various ratios established that Fab2 and Δ C209 P4-P6 form a 1:1 complex (SI Fig. 7).

We then characterized the binding specificity of Fab2 and Fab5 by using three different RNAs (Fig. 3A and B). The Fabs exhibited no detectable affinity for an unrelated RNA oligonucleotide derived from the sarcin/ricin loop of ribosomal RNA (29). Disruption of the P4-P6 fold by mutation of J5/5a (BP P4-P6), so as to form a duplex contiguous with P5 and P5a (30), reduced binding of Fab2 and Fab5 by at least an order of magnitude. The tertiary folding of Δ C209 P4-P6 requires magnesium, and Fab binding strongly depended on magnesium concentration. As the magnesium concentration decreased, binding of Fab2 and Fab5 to Δ C209 P4-P6 was attenuated and became undetectable in the absence of magnesium (Fig. 3C and D). Taken together, these results show that Fabs recognize specifically the tertiary structure of Δ C209 P4-P6.

Strikingly, the Fabs exhibited no detectable affinity (even at concentrations as high as 2 μ M) for the *Tetrahymena* group I intron (L-21), which contains the P4-P6 sequence. The marked discrimination against the intron does not arise from the presence of C209 because Fab2 binds wild-type P4-P6 and Δ C209 P4-P6 with similar affinities (SI Table 2). At lower salt concentration (50 mM NaCl and 10 mM MgCl₂), hydroxyl radical footprinting shows that Fab2 retained some binding to BP P4-P6 but still did not bind the L-21 intron (SI Table 2). The inability of Fab2 to bind L-21 may reflect steric interference from peripheral element loop L2 according to Michel and Westhof's (31) model.

Crystal Structure of the Fab2- Δ C209 P4-P6 Complex. We successfully crystallized the complex of Fab2 with Δ C209 P4-P6 (Fig. 1B), and the crystal structure was determined by molecular replacement (MR) at 1.95 Å (SI Table 3), an improvement over the previous Δ C209 P4-P6 structure at 2.25 Å (20). Although the final structure of the complex was solved by MR using both Fab and RNA models, we found that the Fab MR solution was sufficient to build the RNA model from the resulting electron density maps, demonstrating




Fig. 3. Fab2 and Fab5 bind specifically to the Δ C209 P4-P6 tertiary architecture. (A and B) Graphic representation of fraction RNA bound vs. Fab2 (A) or Fab5 (B) concentration. Fraction bound reflects the 5' 32 P-labeled RNA retained on a nitrocellulose filter (SI Methods). Binding reactions (23°C) contained 10 mM $MgCl_2$, 150 mM NaCl, 10 mM phosphate buffer (pH 7.3), and ≈ 0.3 nM RNA. BP, a P4-P6 mutant designed to form Watson-Crick base pairs in the J4/5 hinge region, rendering P4 and P5 contiguous; SRL, an RNA oligonucleotide containing the sequence of the sarcin/ricin loop derived from the large ribosomal subunit RNA; L-21, a derivative of the *Tetrahymena* group I intron that lacks the first 21 nucleotides. Fab2- and Fab5-binding curves with BP, SRL, and L-21. (C and D) Binding of Δ C209 P4-P6 to Fab2 (C) and to Fab5 (D) depends on Mg^{2+} concentration. Binding curves were fit to the following equation: fraction bound = $f_{max} \times [Fab]^n / ([Fab]^n + K_d^n)$, where f_{max} is the maximum bound fraction at saturating Fab, K_d is the binding affinity, and n is the Hill coefficient, which is generally close to 1.

good phasing capacity of the Fab chaperone (SI Fig. 8). Comparing the Fab2 scaffold (excluding the six CDRs) and the corresponding part of the parent (32) Fab-4D5 gave a C_α rmsd value of 0.7 Å, indicating that the Fab scaffold remains essentially unchanged. Likewise, the RNA portion deviates from the previously determined free Δ C209 P4-P6 with a rmsd of 1.4 Å for C1' atoms (SI Fig. 9), excluding the inherently flexible L6b, the internal loop J6/6a [which interacts with helix P3 in the full-length *Tetrahymena* group I intron (33)] and the end sequences of the RNA, which participate in very different crystal packing interactions compared with the original Δ C209 P4-P6 structure (20). This rmsd value is comparable with 1.2 Å for the two molecules in the asymmetric unit of the Δ C209 P4-P6 structure (20). Therefore, we conclude that the binding of Fab2 does not significantly alter the Δ C209 P4-P6 structure.

As an independent test, we probed the tertiary architecture of Δ C209 P4-P6 complexed with Fab2 in solution by hydroxyl radical footprinting and compared the results to published protection patterns of Δ C209 P4-P6 alone (30, 34). In the presence of Fab2, Δ C209 P4-P6 retains its native protections, suggesting that this RNA maintains its overall structure in the presence of Fab2 in solution and in the crystal. We observe four additional regions of protection in the presence of Fab2: nucleotides 194–196, 174–175, 165–166, and 127–130 (Fig. 1B and SI Fig. 10). These Fab-induced protection sites match the Fab epitope of Δ C209 P4-P6 as revealed by the crystal structure (Fig. 1B).

Binding Interface Between Δ C209 P4-P6 and Fab2. Fab2 binds to Δ C209 P4-P6 with an exceptionally large buried surface area (Fig. 4A), 1,316 Å² (on the Fab side alone), which is almost twice as large as that of most Fab-protein antigen interfaces (777 ± 135 Å²) (35). Consistent with the extensive surface burial, residues from all six CDRs and some scaffold residues form the interface (Fig. 4 and SI




Fig. 4. CDR contribution in Fab2- Δ C209 P4-P6 binding. (A) Molecular surface of the variable domain of Fab2 in the Fab2- Δ C209 P4-P6 structure. Color indicates CDR loop regions in the binding interface as defined by the color scheme legend. Ribbons represent the RNA backbone, with P5a and P5c colored blue and the rest colored light cyan. The green sticks protruding from the RNA ribbon represent the bulged U130. (B) Superposition of the variable domains of Fab2 (light chain, yellow; heavy chain, green) and humanized Fab-4D5 (1FVD, white). Note the large differences in CDR-H3, L2, and H2. (C) Pie chart showing relative contribution of each CDR to the total buried Fab2 surface area (1,316 Å²).

Fig. 11). Superposition of the variable domains reveals significant differences in the main chain conformations of CDR-H3, L2 and H2 compared with the parent (32) Fab-4D5, illustrating the conformational plasticity of the hypervariable regions (Fig. 4B). Within the Fab-RNA interface, CDR-H3 and L2 make direct contact with both P5a and P5c stems and contribute most to the buried surface area: 34% and 29%, respectively (Fig. 4C). This observation suggests that CDR-H3 and L2 likely play significant roles in the recognition of Δ C209 P4-P6, even though L2 was not diversified in the library.

CDR-H3 resides in the center of the P5a/P5c helical interface at the three-helix junction (Fig. 5A). Residues Gly-98, Ser-100, and Thr100a interact with the wide and shallow minor groove of P5c via direct H bonds, and Tyr-102 contacts P5a by H bonding to U131 in the minor groove. Several CDR-H3 residues form a pocket (Fig. 5B) that encloses U130, the bulged uridine in P5a, and they use a variety of molecular strategies to interact with U130. Arg-94, Ala-96, Asp-101, and Gly100c form direct H bonds to the uracil base and sugar ring, whereas the side chains of Ala-96 and Met-99 embrace the nucleotide with nonpolar contacts. Tyr100b stacks perpendicularly with the base, and Arg-94 forms an N-O bridge-type of ion pair with the adjacent phosphate (36). Interestingly, although Arg-95 was selected from the library, it makes no interaction with the RNA in the structure; instead, its side chain points away from the RNA and makes hydrogen bonding interactions with the backbone carbonyl groups of Tyr100b and Met-99, possibly stabilizing the CDR-H3 loop conformation.

CDR-L2 loop residues (defined as residues 50–56) (37) and the flanking framework residues interact extensively with RNA, mainly in the P5a minor groove. Residues Ser-56, Gly-57, and Ser-60 form direct H bonds to the 3' strand of P5a, across from U130 near the hinge region (Fig. 5A). A possible long-range ion pair between Arg-61 and the phosphate moiety of C197 may stabilize this interaction. Direct H bonding between Ser-50 and the U167 phosphate links CDR-L2 to P5c, making L2 another CDR that binds both helical stems. Tyr-49 and Tyr-55 stack perpendicularly with U130 from the nonpolar side to seal the U130-binding pocket generated by CDR-H3 (Fig. 5B). Three water molecules organized by the four tyrosine residues surrounding U130 interact with the sugar-phosphate moiety, which may further strengthen the RNA-Fab interaction at the nonpolar interface of the U130 binding pocket (Fig. 5C).




Fig. 6. Differences in innersphere magnesium ion coordination and a local conformation compared with the previous Δ C209 P4-P6 structure. (A) Innersphere coordinated magnesium ions in the Δ C209 P4-P6 core (cyan spheres) and 3' end region (green sphere). Red spheres indicate missing metal ions observed in Δ C209 P4-P6, but not in the complex with Fab2. (B) A magnesium ion associates with P6 and J6/6a via innersphere coordination to U258 and G257 and outersphere coordination to C255, C216, G215, and G257. (C) Superposition of P6 and J6/6a from the full-length group I intron structure (red) with P6 and J6/6a from the complex (blue) or Δ C209 P4-P6 structure (green).

HDV-U1A crystal structure (41, 42). Thus, as a crystallization chaperone, Fab2 plays an important role in crystal packing via interactions with both protein and RNA.

Discussion

Selection of Anti-RNA Fabs by Phage Display. This work demonstrates the first successful selection of anti-RNA antibody fragments from a synthetic naïve library. Braun *et al.* (43) obtained antipolyinosine antibodies through immunization of mice. Beyond that, the only known examples of anti-RNA antibodies occur pathologically in autoimmune diseases such as systemic lupus erythematosus (14, 44) and rheumatoid arthritis (15). The successful isolation of synthetic Fabs that bind tightly to Δ C209 P4-P6 and to a diverse panel of other structured RNAs (J.-D.Y., Y. Koldobskaya, J. Min, and J.A.P., unpublished work) suggests that the paucity of available anti-RNA antibodies probably reflects nucleolytic instability of RNA during *in vivo* immunization, rather than some fundamental limitation in the ability of natural antibody repertoires to bind RNA. *In vitro* selection using phage display allows for fine adjustment of solution conditions so that the structural integrity of an RNA antigen can be maintained. Moreover, our selected Fabs recognize antigens in a specific manner, probably owing to the inclusion of negative selection with tRNA, which removes Fabs that interact nonspecifically with RNA.

The Fab as an RNA-Binding Protein Scaffold. Despite statistical similarities at the atomic level (see above), Fab2 recognizes RNA in a manner that differs topologically from that of other RNA-binding proteins. RNA-binding proteins often consist of several modular domains that generally have topologically rugged surfaces and engulf regions of the RNA or penetrate into the grooves. In Fab2, the CDR loops form a relatively smooth, shallow surface that recognizes numerous structural features of Δ C209 P4-P6. The CDR-H3 and L2 loops span the binding interface to interact with the wide and flat minor grooves of two adjacent helices (P5a and P5c) at the three-helix junction. Together, these loops also form a binding pocket for the bulged uridine residue (U130) that protrudes from P5a. The remaining CDR loops give the shallow Fab surface a slightly convex curvature, contributing 37% to the buried surface area by recognizing both the ribose-phosphate backbone moiety and the unpaired nucleobases in the single-stranded regions. Possibly, these interactions enhance the binding specificity through both shape complementarity and specific nucleobase recognition.

With the exception of unstructured peptides or arginine-rich motifs, a given type of RNA-binding module usually binds to a

distinct class of RNA structures. Considering the possible diversity in sequence composition, length, and main-chain conformation of the CDRs, Fabs may provide a highly versatile scaffold for binding to a wide range of RNAs. As a preliminary demonstration, we have obtained >100 Fabs in selections against 10 structurally diverse RNA targets (J.-D.Y., Y. Koldobskaya, J. Min, and J.A.P., unpublished work).

Fab2- Δ C209 P4-P6-Binding Interface Suggests Strategies to Improve the Library Design.

The Fab library used in this work successfully produced highly specific and tightly binding Fabs against Δ C209 P4-P6. However, the design of this library is based on bioinformatic analysis of antibodies binding to protein antigens (24). The CDR sequences of our Δ C209 P4-P6-binding Fabs and the Fab2-RNA interface suggest several strategies to improve the library design for RNA targets (1). With respect to CDR-H3, all of our selected clones showed an enrichment for positively charged amino acids, suggesting that increasing Arg content in CDR-H3 may yield a library better suited for selection targeting RNAs (2). The YSG library used herein contains no diversity in CDR-L1 and L2; yet Fab2 uses light-chain CDRs for Δ C209 P4-P6 recognition, especially CDR-L2, which seldom participates in protein antigen recognition. Thus, expanding synthetic diversity to include the L1 and L2 CDR loops might improve the RNA-binding repertoire further (3). With respect to the binary YS code used for CDR-L3, H1 and H2, we find that Ser and Tyr residues contribute 29% and 28%, respectively, to the buried surface area (SI Fig. 13). Twelve different amino acids contribute to the remaining 43%, with Gly and Arg residues contributing most among them. In contrast, Fabs selected against protein antigens from YS-enriched libraries (22, 26, 27) reveal a dominant role for tyrosine residues at the antigen interface, especially in the case of an anti-hVEGF Fab-D1 selected from the same library as used in our selections (24). In the Fab-D1 paratope, Tyr residues contribute 69% of the buried surface area, Ser residues contribute only an additional 18%, and four other residue types contribute the remaining 13%. These striking differences between the protein and RNA-binding paratopes suggest that the YS binary code may not be optimal for RNA antigens, and the inclusion of additional diversity may produce a more robust response against RNA antigens.

Fab Chaperones for the Crystallization of Structured RNA. In this study we have established that an anti-RNA Fab can act as a chaperone to assist crystallization of a large folded RNA, enabling structure determination of the Fab2- Δ C209 P4-P6 complex at 1.95-Å reso-

lution. Fab2 participates extensively in the crystal contacts, contributing 61% of the total surface area buried by crystal lattice interactions, within the range observed for the U1A protein chaperone-mediated lattice interactions (41, 45, 46) (HDV-U1A, 85%; hairpin ribozyme-U1A, 59%; *Azoarcus*-U1A, 28%). In contrast to the U1A chaperone, Fabs circumvent the need to engineer protein-binding sequences into the RNA. Additionally, the 4-fold-larger size of Fab compared with U1A may, in certain cases, have advantages in facilitating RNA crystallization and providing better phasing information (SI Fig. 8). Although the generality of the approach remains to be determined, this Fab-RNA cocrystal establishes proof-of-concept for using Fabs as RNA crystallization chaperones.

Concluding Remarks. The synthetic Fab repertoire used herein has produced highly specific and tight-binding antibody fragments to an elaborately structured RNA. The ability to obtain antibodies that bind RNA targets with high affinity and specificity enables many new clinical and experimental applications in RNA structural, molecular, and cellular biology. Herein, we have demonstrated one such application for RNA crystallization, but others include, for example, the use of anti-RNA antibodies to identify unique RNA markers that certain disease states might carry. Direct immunoprecipitation and visualization of RNA for cellular biological investigations also becomes possible, either by using antibodies selected directly against the RNA of interest or by using an RNA antigen such as P4-P6 as an epitope tag.

Methods

Fab Selection and Production. The Fab phage display library and general library manipulation methods have been described in refs. 24 and 47. Selection was done at room temperature by using the magnetic beads method (25). In the first round, 0.5 nmol of biotinylated Δ C209 P4-P6 (AGGUCGACUCUAGAGGAUCCCGG was added to the 3' end of Δ C209 P4-P6 and annealed to the 5' biotinylated DNA oligonucleotide, 5'-ACCGGGATCCTAGAGTC-3') was immobilized on magnetic beads (Promega) and incubated with $\approx 10^{12-13}$ cfu of phages for 15 min in 1 ml of buffer A [PBS (8 mM Na_2HPO_4 , 1.5 mM KH_2PO_4 , 137 mM NaCl, and 3 mM KCl), 0.05% Tween 20, 2.5 mM EDTA, 12.5 mM MgCl_2 , and 5% glycerol, pH 7.2] supplemented with 0.1 mg/ml BSA, 0.1 mg/ml streptavidin, and 1 unit/ μ l RNase inhibitor (Promega). The solution was then removed, and the beads were washed twice with buffer A. In the subsequent rounds, purified phage pools were first incubated with streptavidin beads in buffer A for 30 min, and the supernatant

was used in the subsequent selection on a KingFisher magnetic particle processor (Thermo Electron Corporation). Phages ($\approx 10^{10-11}$ cfu) were incubated for 15 min with 50 nM biotinylated Δ C209 P4-P6 in 100 μ l of buffer A, supplemented with 0.1 mg/ml BSA, 1 unit/ μ l RNase inhibitor, and 50 μ g/ml *E. coli* tRNA mixture. Streptavidin magnetic beads were then added to the solution for 15 min to allow the capture of the biotinylated Δ C209 P4-P6 together with the bound phages. The beads were then blocked with 50 μ M biotin, washed five times with buffer A, and eluted in 50 μ l of elution buffer (PBS, 5% glycerol, and 1 μ g/ml biotinylated RNase A). The biotinylated RNase A was removed from the resulting phage library by incubation with streptavidin beads. After each round of selection, recovered phages were amplified as described in ref. 47.

After selection, individual clones were grown in a 96-well format in 500 μ l of 2YT broth supplemented with ampicillin and M13-KO7 helper phage. The culture supernatants were used in phage ELISA to detect positive clones that bound to antigen-coated plates, but not to control plates (47). Positive clones were sequenced. Competitive phage ELISA was used to estimate the binding affinities of the unique clones, and Fab proteins of interest were expressed and purified as described in ref. 28.

Filter binding analysis and Hydroxyl radical footprinting are described in *SI Methods*.

Crystallization. Δ C209 P4-P6 (0.194 mM) was incubated at 60°C for 10 min in 10 mM Tris-HCl, pH 7.5, 25 mM MgCl_2 , and 50 mM NaCl and was slowly cooled to room temperature in ≈ 1.5 h. Fab2 protein (1 equivalent) and spermine-4HCl (0.5 mM final concentration) were added to Δ C209 P4-P6 while maintaining the concentration of MgCl_2 and NaCl. The mixture was incubated at room temperature for 30 min and cooled to 4°C over a period of ≈ 0.5 h. Crystallization was set up by using the hanging-drop vapor diffusion method: two volumes of the complex were combined with 1 vol of reservoir buffer (34% 2-methyl-2,4-pentanediol, 0.1 M sodium citrate, pH 5.9, and 0.2 M NH_4OAc) and equilibrated against 0.5 ml of reservoir buffer at 4°C. The crystal clusters appeared in 3 days and grew to their maximum size (≈ 0.1 – 0.15 mm) in ≈ 14 days. For data collection, the crystal clusters were broken into thin plates by using crystal manipulation tools (Hampton Research) and were flash-frozen in liquid nitrogen by using CryoLoops (Hampton Research) directly from the mother liquor. Data collection and structure determination are described in *SI Methods*.

ACKNOWLEDGMENTS. We thank Barbara Golden and the members of the J.A.P. Laboratory for helpful discussions and the staffs of the Structural Biology Center Collaborative Access Team, the Southeast Regional Collaborative Access Team, and the General Medicine and Cancer Institutes Collaborative Access Team for help with data collection. This work was supported by grants from the Howard Hughes Medical Institute (to J.A.P.) and from the U.S. National Institutes of Health (to A.A.K. and S. K.) and by the University of Chicago Cancer Research Center.

- Schrama D, Reisfeld RA, Becker JC (2006) *Nat Rev Drug Discov* 5:147–159.
- Carter PJ (2006) *Nat Rev Immunol* 6:343–357.
- Arrowhead Publishers (2004) *Monoclonal Antibody Therapies: Entering A New Competitive Era* (Arrowhead Publishers, Minneapolis).
- Nielsen UB, Geierstanger BH (2004) *J Immunol Methods* 290:107–120.
- Hunte C, Michel H (2002) *Curr Opin Struct Biol* 12:503–508.
- Giepmans BN, Adams SR, Ellisman MH, Tsien RY (2006) *Science* 312:217–224.
- Davies DR, Cohen GH (1996) *Proc Natl Acad Sci USA* 93:7–12.
- Lucas AH, Reason DC (1999) *Immunol Rev* 171:89–104.
- Livesay DR, Subramaniam S (2004) *Protein Eng Des Sel* 17:463–472.
- Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N, Oyama R, Ravasi T, Lenhard B, Wells C, et al. (2005) *Science* 309:1559–1563.
- Bertone P, Stolc V, Royce TE, Rozowsky JS, Urban AE, Zhu X, Rinn JL, Tongprasit W, Samanta M, Weissman S, et al. (2004) *Science* 306:2242–2246.
- Winkler WC, Breaker RR (2005) *Annu Rev Microbiol* 59:487–517.
- Doudna JA, Cech TR (2002) *Nature* 418:222–228.
- van Venrooij WJ, Hoet R, Castrop J, Hageman B, Mattaj JW, van de Putte LB (1990) *J Clin Invest* 86:2154–2160.
- Kalmakoff J, Maskill WJ, Thongkrajai P, Palmer DG (1981) *Aust N Z J Med* 11:173–178.
- Ohosone Y, Matsumura M, Chiba J, Nagaoka S, Matsuoka Y, Irimajiri S, Mimori T (1998) *Clin Rheumatol* 17:144–147.
- Gilliam AC, Steitz JA (1993) *Proc Natl Acad Sci USA* 90:6781–6785.
- Pokkuluri PR, Bouthillier F, Li Y, Kuderova A, Lee J, Cygler M (1994) *J Mol Biol* 243:283–297.
- Cate JH, Gooding AR, Podell E, Zhou K, Golden BL, Kundrot CE, Cech TR, Doudna JA (1996) *Science* 273:1678–1685.
- Juneau K, Podell E, Harrington DJ, Cech TR (2001) *Structure (London)* 9:221–231.
- Fellouse FA, Wiesmann C, Sidhu SS (2004) *Proc Natl Acad Sci USA* 101:12467–12472.
- Fellouse FA, Li B, Compaan DM, Peden AA, Hymowitz SG, Sidhu SS (2005) *J Mol Biol* 348:1153–1162.
- Wu TT, Johnson G, Kabat EA (1993) *Proteins* 16:1–7.
- Fellouse FA, Esaki K, Birtalan S, Raptis D, Cancasci VJ, Koide A, Jhurani P, Vasser M, Wiesmann C, Kossiakoff AA, et al. (2007) *J Mol Biol* 373:924–940.
- Laird-Offringa IA, Belasco JG (1996) *Methods Enzymol* 267:149–168.
- Fellouse FA, Barthelemy PA, Kelley RF, Sidhu SS (2006) *J Mol Biol* 357:100–114.
- Koide A, Gilbreth RN, Esaki K, Tereshko V, Koide S (2007) *Proc Natl Acad Sci USA* 104:6632–6637.
- Lee CV, Liang WC, Dennis MS, Eigenbrot C, Sidhu SS, Fuh G (2004) *J Mol Biol* 340:1073–1093.
- Korenykh AV, Piccirilli JA, Correll CC (2006) *Nat Struct Mol Biol* 13:436–443.
- Murphy FL, Cech TR (1993) *Biochemistry* 32:5291–5300.
- Michel F, Westhof E (1990) *J Mol Biol* 216:585–610.
- Eigenbrot C, Randal M, Presta L, Carter P, Kossiakoff AA (1993) *J Mol Biol* 229:969–995.
- Guo F, Gooding AR, Cech TR (2004) *Mol Cell* 16:351–362.
- Uchida T, He Q, Ralston CY, Brenowitz M, Chance MR (2002) *Biochemistry* 41:5799–5806.
- Jones S, Thornton JM (1996) *Proc Natl Acad Sci USA* 93:13–20.
- Kumar S, Nussinov R (2002) *Biophys J* 83:1595–1612.
- Kabat EA, Wu TT (1971) *Ann NY Acad Sci* 190:382–393.
- Treger M, Westhof E (2001) *J Mol Recognit* 14:199–214.
- Jeong E, Kim H, Lee SW, Han K (2003) *Mol Cells* 16:161–167.
- Lejeune D, Delsaux N, Charlotiaux B, Thomas A, Brasseur R (2005) *Proteins* 61:258–271.
- Ferre-D'Amare AR, Zhou K, Doudna JA (1998) *Nature* 395:567–574.
- Ferre-D'Amare AR, Doudna JA (2000) *J Mol Biol* 295:541–556.
- Braun RP, Woodsworth ML, Lee JS (1986) *Mol Immunol* 23:685–691.
- Teunissen SW, Stassen MH, Puijck GJ, van Venrooij WJ, Hoet RM (1998) *RNA* 4:1124–1133.
- Rupert PB, Ferre-D'Amare AR (2001) *Nature* 410:780–786.
- Adams PL, Stahley MR, Kosek AB, Wang J, Strobel SA (2004) *Nature* 430:45–50.
- Sidhu SS, Lowman HB, Cunningham BC, Wells JA (2000) *Methods Enzymol* 328:333–363.